title: A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy.
abstract: OBJECTIVE
  To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.
  
  
  METHODS
  Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43).
  
  
  RESULTS
  Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P < 0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion.
  
  
  CONCLUSIONS
  In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.
authors.affiliation: Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands. a.alkhalaf@int.umcg.nl
authors.forename: Alaa
authors.initials: A
authors.lastname: Alkhalaf
authors.forename: Astrid
authors.initials: A
authors.lastname: Klooster
authors.forename: Willem
authors.initials: W
authors.lastname: van Oeveren
authors.forename: Ulrike
authors.initials: U
authors.lastname: Achenbach
authors.forename: Nanne
authors.initials: N
authors.lastname: Kleefstra
authors.forename: Robbert J
authors.initials: RJ
authors.lastname: Slingerland
authors.forename: G Sophie
authors.initials: GS
authors.lastname: Mijnhout
authors.forename: Henk J G
authors.initials: HJ
authors.lastname: Bilo
authors.forename: Reinold O B
authors.initials: RO
authors.lastname: Gans
authors.forename: Gerjan J
authors.initials: GJ
authors.lastname: Navis
authors.forename: Stephan J L
authors.initials: SJ
authors.lastname: Bakker
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000188:drug therapy* / Q000652:urine; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000652:urine; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000652:urine; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D000072596:Hepatitis A Virus Cellular Receptor 1; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects; D008297:Male; D008562:Membrane Glycoproteins / Q000652:urine; D008875:Middle Aged; D010919:Placebos; D011991:Receptors, Virus; D013831:Thiamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D000276:Adjuvants, Immunologic; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; C491143:HAVCR1 protein, human; D000072596:Hepatitis A Virus Cellular Receptor 1; D008562:Membrane Glycoproteins; D010919:Placebos; D011991:Receptors, Virus; D013831:Thiamine; C013835:benphothiamine